Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Rizzieri

Showing results (11-20 of 132) with videos related to

Pageof 14
Sort By:
European Journal of Haematology|May 6, 2016
Insight into the molecular pathophysiology of myelodysplastic syndromes: targets for novel therapyMohammad Faizan Zahid, Mrinal M Patnaik, Naseema Gangat, et al.
Chest|August 11, 2004
Pulmonary sarcoidosis following stem cell transplantation: is it more than a chance occurrence?Rajesh Bhagat, David A Rizzieri, James J Vredenburgh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2005
Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemiaRyan H Shanks, David A Rizzieri, James L Flowers, et al.
Leukemia & Lymphoma|April 10, 2008
Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cellsDavid J Adams, Marit L Sandvold, Finn Myhren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2019
Targeting High Mobility Group Box-1 (HMGB1) Promotes Cell Death in Myelodysplastic SyndromeAngel Y F Kam, Sadhna O Piryani, Chad M McCall, et al.
Leukemia & Lymphoma|January 7, 2016
An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemiaDavid A Rizzieri, Sarah Cooley, Olatoyosi Odenike, et al.
American Journal of Hematology|June 20, 2015
A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapyPatrick T Griffin, Rami S Komrokji, Carlos M De Castro, et al.
Molecular Cancer Research : MCR|January 30, 2021
Selective ERBB2 and BCL2 Inhibition Is Synergistic for Mitochondrial-Mediated Apoptosis in MDS and AML CellsAngel Y F Kam, Sadhna O Piryani, Chang-Lung Lee, et al.
American Journal of Hematology|July 25, 2003
High-dose cyclophosphamide and etoposide for patients with refractory acute myeloid leukemia: a case seriesJeffrey Talbot, David A Rizzieri, Carlos M DeCastro, et al.
Leukemia & Lymphoma|December 17, 2025
Durable post-transplant survival after first-line tagraxofusp for blastic plasmacytoid dendritic cell neoplasmNaveen Pemmaraju, Marina Konopleva, Muzaffar Qazilbash, et al.
Pageof 14

Showing results (11-20 of 132) with videos related to

Sort By:
Pageof 14
European Journal of Haematology|May 6, 2016
Insight into the molecular pathophysiology of myelodysplastic syndromes: targets for novel therapyMohammad Faizan Zahid, Mrinal M Patnaik, Naseema Gangat, et al.
Chest|August 11, 2004
Pulmonary sarcoidosis following stem cell transplantation: is it more than a chance occurrence?Rajesh Bhagat, David A Rizzieri, James J Vredenburgh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2005
Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemiaRyan H Shanks, David A Rizzieri, James L Flowers, et al.
Leukemia & Lymphoma|April 10, 2008
Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cellsDavid J Adams, Marit L Sandvold, Finn Myhren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2019
Targeting High Mobility Group Box-1 (HMGB1) Promotes Cell Death in Myelodysplastic SyndromeAngel Y F Kam, Sadhna O Piryani, Chad M McCall, et al.
Leukemia & Lymphoma|January 7, 2016
An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemiaDavid A Rizzieri, Sarah Cooley, Olatoyosi Odenike, et al.
American Journal of Hematology|June 20, 2015
A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapyPatrick T Griffin, Rami S Komrokji, Carlos M De Castro, et al.
Molecular Cancer Research : MCR|January 30, 2021
Selective ERBB2 and BCL2 Inhibition Is Synergistic for Mitochondrial-Mediated Apoptosis in MDS and AML CellsAngel Y F Kam, Sadhna O Piryani, Chang-Lung Lee, et al.
American Journal of Hematology|July 25, 2003
High-dose cyclophosphamide and etoposide for patients with refractory acute myeloid leukemia: a case seriesJeffrey Talbot, David A Rizzieri, Carlos M DeCastro, et al.
Leukemia & Lymphoma|December 17, 2025
Durable post-transplant survival after first-line tagraxofusp for blastic plasmacytoid dendritic cell neoplasmNaveen Pemmaraju, Marina Konopleva, Muzaffar Qazilbash, et al.
Pageof 14